ArticleFrontiers in genetics2025
Identification of biomarkers associated with mitochondrial dysfunction and programmed cell death in chronic obstructive pulmonary disease via transcriptomics.
Article in Frontiers in genetics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Mitochondrial Dysfunction: From Molecular Mechanisms to Modern Approaches for Basic and Clinical Research.Biomedicines · 2026Review
- Decoding serum C-reactive protein-associated molecular patterns in aging and secondhand smoke exposure chronic obstructive pulmonary disease male patients: evidence from cross-sectional, multi-omic and clinical studies.Frontiers in medicine · 2026Article
- The role of programmed cell death in chronic obstructive pulmonary disease: from pathogenesis to treatment.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Research has demonstrated that the homeostasis of mitochondria and programmed cell death (PCD) are intimately linked to chronic obstructive pulmonary disease (COPD). Consequently, identifying biomarkers of COPD from mitochondria-related genes (MRGs) and programmed cell death-related genes (PCD-RGs) is of paramount importance. Methods: Differentially expressed genes (DEGs) from the GSE42057 dataset and COPD-related genes (COPD-RGs) via weighted gene co-expression network analysis (WGCNA) were intersected with MRGs and PCD-RGs to select candidates. Machine learning identified biomarkers, validated across GSE42057 and GSE94916 datasets. Pathway enrichment, immune infiltration, and drug prediction analyses were performed. Results: Eight candidate genes were derived from intersecting DEGs, COPD-RGs, MRGs, and PCD-RGs. Five biomarkers (BCL2, CCR7, FAM162A, FOXO1, RPS3) were identified, showing consistent dysregulation in COPD. These biomarkers activated the "ribosome" pathway. CCR7 and FOXO1 correlated positively with naïve B cells, while BCL2 negatively correlated with M0 macrophages. BCL2 exhibited strong binding to dolastatin 10, beauvericin, and micellar paclitaxel. RT-qPCR confirmed biomarker expression. Conclusion: BCL2, CCR7, FAM162A, FOXO1, and RPS3 are biomarkers for COPD, providing a new breakthrough point for the treatment of this disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.